NB200-174

antibody from Novus Biologicals

Targeting: CDKN2A ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Immunoprecipitation (Recommended by provider)

Immunohistochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Antibody Data

Product number

NB200-174

Provider

Novus Biologicals

Proper citation

Novus Cat#NB200-174, RRID:AB_10002046

Product name

p19ARF Antibody

Antibody type

Monoclonal

Antigen

A synthetic peptide containing amino acids 54-75 of the murine p19ARF.

Reactivity

Human, Mouse

Host

Rat

Isotype

IgG

Vial size

0.1 ml

Concentration

1 mg/ml

References

Submitted references

Senescent Kidney Cells in Hypertensive Patients Release Urinary Extracellular Vesicles.

Santelli A, Sun IO, Eirin A, Abumoawad AM, Woollard JR, Lerman A, Textor SC, Puranik AS, Lerman LO
Journal of the American Heart Association 2019 Jun 4;8(11):e012584

---

Ezh2 programs T_FH differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf.

Li F, Zeng Z, Xing S, Gullicksrud JA, Shan Q, Choi J, Badovinac VP, Crotty S, Peng W, Xue HH
Nature communications 2018 Dec 21;9(1):5452

---

Detection of Oncogene-Induced Senescence In Vivo.

Baek KH, Ryeom S
Methods in molecular biology (Clifton, N.J.) 2017;1534:185-198

---

Hepatocellular carcinoma repression by TNFα-mediated synergistic lethal effect of mitosis defect-induced senescence and cell death sensitization.

Li D, Fu J, Du M, Zhang H, Li L, Cen J, Li W, Chen X, Lin Y, Conway EM, Pikarsky E, Wang H, Pan G, Ji Y, Wang HY, Hui L
Hepatology (Baltimore, Md.) 2016 Oct;64(4):1105-20

---

An extra copy of p53 suppresses development of spontaneous Kras-driven but not radiation-induced cancer.

Moding EJ, Min HD, Castle KD, Ali M, Woodlief L, Williams N, Ma Y, Kim Y, Lee CL, Kirsch DG
JCI insight 2016 Jul 7;1(10)

---

Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma.

Lee CL, Castle KD, Moding EJ, Blum JM, Williams N, Luo L, Ma Y, Borst LB, Kim Y, Kirsch DG
Nature communications 2015 Sep 24;6:8477

---

AKT regulates NPM dependent ARF localization and p53mut stability in tumors.

Hamilton G, Abraham AG, Morton J, Sampson O, Pefani DE, Khoronenkova S, Grawenda A, Papaspyropoulos A, Jamieson N, McKay C, Sansom O, Dianov GL, O'Neill E
Oncotarget 2014 Aug 15;5(15):6142-67

---

A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis.

Olive V, Sabio E, Bennett MJ, De Jong CS, Biton A, McGann JC, Greaney SK, Sodir NM, Zhou AY, Balakrishnan A, Foth M, Luftig MA, Goga A, Speed TP, Xuan Z, Evan GI, Wan Y, Minella AC, He L
eLife 2013 Oct 15;2:e00822

---

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.

Shchors K, Persson AI, Rostker F, Tihan T, Lyubynska N, Li N, Swigart LB, Berger MS, Hanahan D, Weiss WA, Evan GI
Proceedings of the National Academy of Sciences of the United States of America 2013 Apr 16;110(16):E1480-9

---

Polycomb (PcG) proteins, BMI1 and SUZ12, regulate arsenic-induced cell transformation.

Kim HG, Kim DJ, Li S, Lee KY, Li X, Bode AM, Dong Z
The Journal of biological chemistry 2012 Sep 14;287(38):31920-8

---

Role of Pirh2 in mediating the regulation of p53 and c-Myc.

Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, Jung YS, Karaskova J, Kaustov L, Duan S, Madore J, Boutros P, Sheng Y, Chesi M, Bergsagel PL, Perez-Ordonez B, Mes-Masson AM, Penn L, Squire J, Chen X, Jurisica I, Arrowsmith C, Sanchez O, Benchimol S, Hakem R
PLoS genetics 2011 Nov;7(11):e1002360

---

Validation of MdmX as a therapeutic target for reactivating p53 in tumors.

Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegué E, Evan GI
Genes & development 2011 Aug 15;25(16):1746-57

---

Distinct thresholds govern Myc's biological output in vivo.

Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI
Cancer cell 2008 Dec 9;14(6):447-57

---

Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis.

Bertwistle D, Sherr CJ
Blood 2007 Jan 15;109(2):792-4

---

Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex.

Klochendler-Yeivin A, Picarsky E, Yaniv M
Molecular and cellular biology 2006 Apr;26(7):2661-74

---

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

Williams RT, Roussel MF, Sherr CJ
Proceedings of the National Academy of Sciences of the United States of America 2006 Apr 25;103(17):6688-93

---

Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.

Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW, Quelle DE
Molecular and cellular biology 2005 Feb;25(4):1258-71

---

Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein.

Bertwistle D, Zindy F, Sherr CJ, Roussel MF
Hybridoma and hybridomics 2004 Oct;23(5):293-300

Western blot

Supportive validation

Submitted by

Novus Biologicals (provider)

Main image

Experimental details

Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Analysis of endogenous p19Arf. Total cell lysates (25 ug) from NIH3T3 cells, which have deleted the Arf gene (Lanes 1) and from wild type mouse embryo fibroblasts (MEFs) at passage 6, which express p19Arf (Lanes 2), were resolved by SDS-PAGE.

Supportive validation

Submitted by

Novus Biologicals (provider)

Main image

Experimental details

Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Total cell lysates (250 ug) from NIH3T3 cells which have deleted the Arf gene (Lanes 5) and from NIH3T3 cells expressing an HA-tagged version of p19Arf (lanes 3, 4) were incubated with control rat IgG (Lanes 3), or NB200-174 (lanes 4, 5) and protein G- Sepharose. Precipitated proteins were resolved by SDS-PAGE and analysed by Western blotting using an anti-HA antibody. Unprecipitated total cell lysates (25 ug, equivalent to 10% of immunoprecipitation) from Arf null NIH3T3 cells (Lanes 1) and HA- p19Arf expressing cells (Lanes 2) were also analysed by Western blotting, as input controls.

Supportive validation

Submitted by

Novus Biologicals (provider)

Main image

Experimental details

Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Whole cell protein from mouse Neuro2A and MEF cells was separated on a 4-20% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-p19ARF in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.

Immunohistochemistry

Supportive validation

Submitted by

Novus Biologicals (provider)

Main image

Experimental details

Immunohistochemistry: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Staining of sections from a wild type mouse testis taken at P11 were probed with NB200-174 (green). Sections were stained with DAPI to reveal the position of cell nuclei (blue).

Flow cytometry

Supportive validation

Submitted by

Novus Biologicals (provider)

Main image

Experimental details

Flow (Intracellular): p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - An intracellular stain was performed on HEK293 cells with p14ARF (5-C3-1) antibody NB200-174 (blue) and a matched isotype control MAB0061 (orange) [A]. An intracellular stain was also performed on THP-1 (known homozygous deletion of gene, PMID: 19635138) cells to ensure antibody specificity [B]. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Goat Anti-Rat F(ab)2 IgG (H+L) APC-conjugated Antibody (F0113, R&D Systems). *Note: This antibody recognizes both human (p14ARF) and mouse (p19ARF) versions of the protein.